In 1981 after the introduction of cyclosporin and the development of a new surgical technique, heart-lung transplantation began to yield satisfactory results. First introduced as a treatment for pulmonary vascular disease, heart-lung transplantation was extended to treat end stage lung disease2 and then cystic fibrosis.3 Since 1984 we have performed 51 heart-lung transplantations. As experience increased and survival improved4 recipient selection was expanded to include older and younger patients. We report here our experience in five children under the age of 16 years (range 11-15 years) who had a heart-lung transplantation between May 1987 and October 1988.
Patients and methods
Between March 1985 and October 1988 , 33 children below the age of 16 were referred for assessment of their suitability for heart-lung transplantation.
Thirty of these have been assessed and 15 were placed on the active waiting list for transplantation. Ten were considered to be suitable but not sufficiently disabled to require transplantation and were placed on a 'provisional' waiting list. Five patients were felt to be unsuitable, four because they were too well and the other because of profound intellectual difficulties. Two The technique for heart-lung transplantation has been previously described.8 9 All grafts were distantly procured at the donor hospital. The ischaemic times were 150-188 minutes. Immunosuppression was maintained with oral cyclosporin and azathioprine. The dose of cyclosporin was adjusted to give a whole blood concentration of less than 1000 ,g/ml, a plasma concentration less than 300 ig/ml, and a concentration of azathioprine to keep the total white cell count above 5-0x109/l. Rejection episodes were treated with intravenous methylprednisolone 500 mg, daily for three days followed by oral i ednisolone 1 (table 2) .
The preoperative diagnosis in patient 2 was thought to be Eisenmenger's syndrome secondary to an ostium primum atrial septal defect. On examination of the explanted organs no intracardiac shunt was shown and a diagnosis of primary pulmonary hypertension was made.
Mean time from acceptance onto the waiting list and transplantation was 2-4 months. The predicted total lung capacity for the donor'4 and the measured total lung capacity for the recipient showed that satisfactory size matching was achieved ( Bleeding from the chest wall Herpes simplex pneumonitis 4 5 5 for age and carpal bone ages were three and four years, respectively, behind their chronological ages. Patient 1, whose height at the time of heart-lung transplantation was above the 50th centile, 15 months later has a height just above the 25th centile, probably the effect of repeated courses of prednisolone required to treat rejection episodes.
Discussion
After success in adults, cardiac transplantation is now an accepted treatment for children with end stage -cardiac disease. 15-17 Our early experience suggests that heart-lung transplantation is an acceptable procedure in children.
The number of children who may benefit from heart-lung transplantation may be assessed by examining the mortality statistics for the age group 5-15 in England and Wales. In 1986 the number of deaths for cystic fibrosis, Eisenmenger's syndrome, and primary pulmonary hypertension, were 40, 17, and three respectively. The number of patients represented with primary pulmonary hypertension may be an underestimate because, as our second case clearly illustrates, it may not be possible to diagnose it in life. This may also be true for Eisenmenger's syndrome where the diagnosis is frequently omitted from death certificates.
Patients are selected if they are considered to have a poor prognosis. In primary pulmonary hypertension, prognosis appears to be associated with low mixed venous oxygen saturation (Si'02%). Fuster et al have shown that patients with an SvO2% below 63% have only a 17% chance of surviving untreated for three years, and those with an Si'02% of 63% or above have a 55% chance of surviving this period.'8 Survival in untreated Eisenmenger's syndrome is more difficult to predict and we have been guided largely by the patient's symptoms. We are currently evaluating the minimum arterial oxygen saturation and distance walked in the 12 minutes as an indication of cardiorespiratory disability.5 In heart disease a raised pulmonary vascular resistance precludes heart transplantation,'5 and for these patients heartlung transplantation is a therapeutic option.
Hypoxic hypercapnic respiratory failure associated with right axis deviation on the electrocardiogram is an ominous sign in cystic fibrosis.19 The FEV,, a further prognostic indicator,20 was below 30% of the predicted value in all of the patients with cystic fibrosis accepted onto our waiting list. 3 Contraindications to heart-lung transplantation include other organ dysfunction. This is particularly relevant in patients with cystic fibrosis. Evidence In our series of 51 recipients of heart-lung transplants we have had five cases of herpes simplex pneumonitis. Herpes simplex pneumonitis has been previously reported in recipients of heart-lung transplants, but proved fatal.25 The prompt diagnosis by transbronchial biopsy and early treatment with acyclovir contributed to a successful outcome in patient 4. The actuarial survival of 78% and 68% at one and two years respectively that we have reported for all heart-lung transplant recipients supports an optimistic outlook for transplantation in children. 4 
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